A Single Patient IND for PD-0325901
A Phase I Single Patient IND for PD-0325901
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92123
- Sharp HealthCare
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Prior treatment with PD-0325901 with ongoing response
Exclusion Criteria:
- none
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 130596 SHRP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prior Treatment With PD-0325901 With Ongoing Clinical Response
-
NCT01244451CompletedPatients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or | Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines
-
NCT02173171CompletedAny Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial
-
NCT07173868RecruitingHistologically Confirmed Metastatic or Locally Advanced Breast Cancer With no Radical Topical Treatment Available | If There is Liver Metastasis, Which the Researcher Believes Will be Difficult to Evaluate the Response Accurately With Bone Metastasis or CT
-
NCT06693349CompletedTo Evaluate the Clinical and Radiographic Effect of Platelet-rich Fibrin in Treatment of Necrotic Permanent Teeth with Open Apices
-
NCT07337551Not yet recruitingPatients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment
-
NCT06477991Recruiting
-
NCT06992024Active, not recruitingElectroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer
-
NCT07006012RecruitingLymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)
-
NCT03482882CompletedTreatment of Depression in Adults With Parkinson's Disease (PD)
Clinical Trials on PD-0325901
-
NCT07237100RecruitingMetastatic Melanoma | Advanced Unresectable Melanoma
-
NCT02096471CompletedNeurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN
-
NCT00174369TerminatedCarcinoma, Non-Small-Cell Lung
-
NCT03962543Active, not recruitingPlexiform Neurofibroma | Neurofibromatosis Type 1 (NF1)
-
NCT03905148Completed
-
NCT04923126RecruitingLow-Grade Glioma | Recurrent Low-Grade Glioma | Progressive Low-Grade Glioma
-
NCT02022982CompletedSolid Tumors | KRAS Mutant Non-Small Cell Lung Cancer
-
NCT06997276RecruitingHealthy | Hepatic Impairment
-
NCT00147550TerminatedMelanoma | Breast Neoplasms | Colonic Neoplasms